Skip to main content Accessibility help
×
Hostname: page-component-848d4c4894-r5zm4 Total loading time: 0 Render date: 2024-07-02T06:45:15.839Z Has data issue: false hasContentIssue false

97 - HIV-1 Infection: Antiretroviral Therapy

from Part XII - HIV

Published online by Cambridge University Press:  05 March 2013

Dionissios Neofytos
Affiliation:
Jefferson Medical College of Thomas Jefferson University
Kathleen E. Squires
Affiliation:
Jefferson Medical College of Thomas Jefferson University
David Schlossberg
Affiliation:
Temple University School of Medicine, Philadelphia
Get access

Summary

Significant progress has been made in the management of HIV-1 disease since 1987, when the first antiretroviral agent, zidovudine, was released. Four classes of antiretrovirals are currently used for the treatment of HIV-1: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), and fusion inhibitors (FIs). A combination of two NRTIs with one NNRTI or PI comprises the standard antiretroviral treatment regimen, also known as highly active antiretroviral therapy (HAART). As of the beginning of 2007, 22 agents have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV-1 (Table 97.1). The goal of antiretroviral treatment is to achieve maximal viral suppression and thus preserve the immune function of the patient and delay the clinical progression of HIV-1 disease. Treating HIV-infected patients requires commitment from both the caregiver and the patient, perpetual counseling and support, and judicial use of the available diagnostic and therapeutic tools by the clinician. Measurement of plasma HIV-1 RNA levels (viral load, VL) and CD4+ cell count is routinely used to monitor therapy. With the new ultrasensitive polymerase chain reaction (PCR) methods, reliable detection of 50 viral copies/mL or more can be accomplished. Failure to achieve undetectable levels of plasma HIV-1 RNA may suggest incomplete compliance, drug resistance, or unfavorable pharmacokinetics.

In this chapter the following topics are discussed: treatment initiation, antiretroviral drugs, recommended first-line antiretroviral regimens, and management of HIV infection during pregnancy.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×